MarketInOut Stock Screener Log In | Sign Up

Agenus Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 11/16/2026 16:00
Agenus Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization304.51 mln
Float39.99 mln
Earnings Date03/16/2027

EPS

0.23
Marginal

P / E

27.35
Elevated

Piotroski F-Score

6 / 9
Solid

Beneish M-Score

57.54
Highly suspicious

1-Year Forecast

27.00
Transformational upside

Relative Strength

37 / 100
Underperforming

Business Description

Agenus Inc. is a US-based biotechnology company focused on developing treatments that use the body's immune system to fight cancer and infectious diseases. Founded in 1994 and headquartered in Lexington, Massachusetts, the company has built a broad pipeline of experimental drugs, several of which are currently in clinical trials. Agenus works alongside major pharmaceutical partners including Bristol-Myers Squibb, Merck, Gilead Sciences, and Incyte Corporation to advance these treatments toward patients.

Key Fundamentals

EPS0.23
P/E27.35
ROE-15.48
RPS3.03
ROIC18.93
ROA45.77
Interest Cover0.88
EBITDA, mln87.23
EV / EBITDA6.69
EV / EBIT6.82
Revenue, mln134
EV / Revenue4.36

Quote Details

Last 6.29
Change -0.44 (-6.54%)
Open 6.60
Volume 566,357
Turnover 3,562,386
Average Volume 684,170

Financial Ratios

Pre-Tax Profit Margin69
Current Ratio0.34
Price / Sales2.07
PEG Ratio1.44

Financial Strength

Altman Z-Score-14.27
Piotroski F-Score 6 / 9
Beneish M-Score57.54
1-Year Target Price27.00
Short Ratio8.23
Short % of Float17.00

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -12.03% 17 / 100   
1 Month 4.14% 85 / 100   
2 Months -7.91% 46 / 100   
6 Months 99.05% 99 / 100   
1 Year 45.27% 92 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog